About Neumedics

---

NeuMedics is an early-stage biotechnology company advancing NM320, a first-in-class topical therapy designed to stabilize mitochondrial dysfunction and help protect retinal cells early in dry age-related macular degeneration.

The company began with a scientific conviction that retinal degeneration, like neurodegeneration in the brain, is driven by changes in cellular energy long before irreversible damage occurs. NeuMedics was formed to explore that idea and develop therapies that could intervene earlier in the disease process.

Over time, the program focused on a modified tetracycline compound delivered as a topical eye drop. What kept the work moving forward was the data. Studies demonstrating retinal penetration, cell protection, and activity in preclinical models reinforced the decision to continue advancing NM320.

Today, NeuMedics is led by experienced scientists and drug developers, including Mark Nelson, PhD, a recognized expert in tetracycline chemistry, as the company prepares for early clinical development.